JP2011515497A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011515497A5 JP2011515497A5 JP2011502076A JP2011502076A JP2011515497A5 JP 2011515497 A5 JP2011515497 A5 JP 2011515497A5 JP 2011502076 A JP2011502076 A JP 2011502076A JP 2011502076 A JP2011502076 A JP 2011502076A JP 2011515497 A5 JP2011515497 A5 JP 2011515497A5
- Authority
- JP
- Japan
- Prior art keywords
- expression product
- patient
- level
- hematological proliferative
- proliferative disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3970108P | 2008-03-26 | 2008-03-26 | |
| US61/039,701 | 2008-03-26 | ||
| PCT/US2009/038462 WO2009120905A2 (en) | 2008-03-26 | 2009-03-26 | Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011515497A JP2011515497A (ja) | 2011-05-19 |
| JP2011515497A5 true JP2011515497A5 (https=) | 2013-05-23 |
Family
ID=41114735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011502076A Withdrawn JP2011515497A (ja) | 2008-03-26 | 2009-03-26 | 骨髄性血液学的増殖性疾患と関連する免疫グロブリンおよび／またはＴｏｌｌ様受容体タンパク質ならびにその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US8709715B2 (https=) |
| EP (2) | EP2271672B1 (https=) |
| JP (1) | JP2011515497A (https=) |
| CN (1) | CN102046660A (https=) |
| WO (3) | WO2009120903A2 (https=) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2472856B (en) * | 2009-08-21 | 2012-07-11 | Cantargia Ab | IL1-RAP modulators and uses thereof |
| PH12012500881A1 (en) | 2009-12-10 | 2017-07-26 | Hoffmann La Roche | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
| CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| CA2789076C (en) | 2010-03-05 | 2017-11-21 | F. Hoffmann-La Roche Ag | Antibodies against human colony stimulating factor-1 receptor and uses thereof |
| RU2597831C2 (ru) | 2011-01-19 | 2016-09-20 | Кантаргия Аб | Анти-il1rap антитела и их применение при лечении людей |
| US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
| WO2013023015A2 (en) * | 2011-08-11 | 2013-02-14 | Albert Einstein College Of Medicine Of Yeshiva University | Targets for diagnosis, prognosis and therapy of acute myeloid leukemia and myelodysplastic syndromes |
| BR112014012624A2 (pt) | 2011-12-15 | 2018-10-09 | F Hoffmann-La Roche Ag | anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo |
| US10196614B2 (en) | 2012-09-18 | 2019-02-05 | University Of Washington Through Its Center For Commercialization | Compositions and methods for antigen targeting to CD180 |
| WO2014100772A1 (en) * | 2012-12-21 | 2014-06-26 | Cellerant Therapeutics, Inc. | Antibodies that bind membrane-bound il1rap |
| AR095882A1 (es) | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9 |
| WO2015014376A1 (en) * | 2013-07-31 | 2015-02-05 | Biontech Ag | Diagnosis and therapy of cancer involving cancer stem cells |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| SG10201900002QA (en) | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| EP3099717B1 (en) | 2014-01-31 | 2019-03-27 | Novartis AG | Antibody molecules to tim-3 and uses thereof |
| US10066014B2 (en) | 2014-02-06 | 2018-09-04 | Yeda Research And Development Co. Ltd. | Anti CD84 antibodies, compositions comprising same and uses thereof |
| GB201403875D0 (en) | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| US20150259420A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| GB201413913D0 (en) | 2014-08-06 | 2014-09-17 | Cantargia Ab | Novel antibodies and uses thereof |
| ES2771926T3 (es) | 2014-09-13 | 2020-07-07 | Novartis Ag | Terapias de combinación |
| CN107109494B (zh) | 2014-11-10 | 2023-10-27 | 豪夫迈·罗氏有限公司 | Il-33介导型疾病的治疗方法和诊断方法 |
| TWI705976B (zh) | 2014-11-10 | 2020-10-01 | 美商建南德克公司 | 抗介白素-33抗體及其用途 |
| AU2016229201B2 (en) | 2015-03-06 | 2021-01-28 | The Board Of Regents Of The University Of Texas System | Anti-LILRB antibodies and their use in detecting and treating cancer |
| BR112017020952A2 (pt) * | 2015-04-13 | 2018-07-10 | Five Prime Therapeutics Inc | método de tratamento de câncer, composição e uso da composição |
| JP7114460B2 (ja) | 2015-06-26 | 2022-08-08 | サノフィ・バイオテクノロジー | モノクローナル抗ＩＬ－１ＲＡｃＰ抗体 |
| DK3317301T3 (da) | 2015-07-29 | 2021-06-28 | Immutep Sas | Kombinationsterapier omfattende antistofmolekyler mod lag-3 |
| AU2016350705A1 (en) | 2015-11-02 | 2018-05-17 | Janssen Pharmaceutica Nv | Anti-IL1RAP antibodies, bispecific antigen binding molecules that bind IL1RAP and CD3, and uses thereof |
| WO2017191627A1 (en) * | 2016-05-02 | 2017-11-09 | Ramot At Tel-Aviv University Ltd. | Antibodies to interleukin 13 receptor alpha-1 (il-13r alpha 1) and uses thereof |
| EP3241845A1 (en) | 2016-05-06 | 2017-11-08 | MAB Discovery GmbH | Humanized anti-il-1r3 antibodies |
| TWI781934B (zh) | 2016-05-27 | 2022-11-01 | 美商艾吉納斯公司 | 抗-tim-3抗體及其使用方法 |
| CN106831998B (zh) * | 2016-06-22 | 2020-09-15 | 徐州医科大学 | 一种人il1rap特异性car及其应用 |
| MY200602A (en) | 2016-07-14 | 2024-01-04 | Bristol Myers Squibb Co | Antibodies against tim3 and uses thereof |
| CN109790220A (zh) | 2016-08-25 | 2019-05-21 | 豪夫迈·罗氏有限公司 | 与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药 |
| US10253371B2 (en) * | 2016-08-29 | 2019-04-09 | National Guard Health Affairs | Method of treating leukemia based on gene expression of clock genes |
| CA3084459A1 (en) | 2016-10-16 | 2018-04-19 | Cellerant Therapeutics, Inc. | Anti-il1-rap antibodies |
| CN110072553B (zh) | 2016-12-22 | 2023-09-15 | 豪夫迈·罗氏有限公司 | 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗 |
| EP3401332A1 (en) | 2017-05-08 | 2018-11-14 | MAB Discovery GmbH | Anti-il-1r3 antibodies for use in inflammatory conditions |
| CA3066918A1 (en) | 2017-06-12 | 2018-12-20 | Bluefin Biomedicine, Inc. | Anti-il1rap antibodies and antibody drug conjugates |
| US20210309752A1 (en) * | 2018-08-03 | 2021-10-07 | The Trustees Of Indiana University | Methods for targeting, inhibiting, and treating a tumoral microenvironment |
| TW202021618A (zh) | 2018-08-17 | 2020-06-16 | 美商２３與我有限公司 | 抗ｉｌ１ｒａｐ抗體及其使用方法 |
| US20200345725A1 (en) | 2019-01-11 | 2020-11-05 | Omeros Corporation | Methods and Compositions for Treating Cancer |
| AU2021236306A1 (en) | 2020-03-13 | 2022-09-15 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| AU2021404495A1 (en) * | 2020-12-17 | 2023-07-27 | Astrazeneca Ab | Anti-il5r antibody formulations |
| CN113238061B (zh) * | 2021-07-09 | 2021-10-01 | 中南大学湘雅医院 | 以cd180阴性b细胞指示重症肌无力病情的试剂盒及应用 |
| CN113408480B (zh) * | 2021-07-13 | 2022-09-30 | 上海交通大学医学院附属瑞金医院 | 基于骨髓细胞形态学的血液疾病人工智能辅助诊断系统 |
| AU2023345467A1 (en) | 2022-09-21 | 2025-05-08 | Sanofi Biotechnology | Humanized anti-il-1r3 antibody and methods of use |
| CN119786008B (zh) * | 2024-11-13 | 2025-11-14 | 南阳市中心医院 | 基于血液中生物标志物预测烟雾病的临床决策支持方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| SG41929A1 (en) | 1992-09-25 | 1997-08-15 | Commw Scient Ind Res Org | Target binding polypeptide |
| PE64396A1 (es) * | 1995-01-23 | 1997-01-28 | Hoffmann La Roche | Proteina accesoria del receptor de la interleucina 1 |
| US6974682B1 (en) * | 1996-08-26 | 2005-12-13 | Human Genome Sciences, Inc. | Soluble interleukin-1 receptor accessory molecule |
| US6280955B1 (en) * | 1997-12-16 | 2001-08-28 | Tularik Inc. | Interleukin-1 receptor accessory proteins, nucleic acids and methods |
| CN101289511A (zh) * | 2000-04-11 | 2008-10-22 | 杰南技术公司 | 多价抗体及其应用 |
| WO2002064630A2 (en) * | 2000-10-31 | 2002-08-22 | Immunex Corporation | Il-1 receptor accessory protein |
| WO2005019258A2 (en) * | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| EP1682903A2 (en) * | 2003-11-04 | 2006-07-26 | Roche Diagnostics GmbH | Method for distinguishing aml-specific flt3 length mutations from tkd mutations |
| KR20120064120A (ko) * | 2004-06-01 | 2012-06-18 | 제넨테크, 인크. | 항체 약물 접합체 및 방법 |
| BRPI0607753A2 (pt) * | 2005-02-16 | 2009-10-06 | Wyeth Corp | método para prever um efeito clìnico em resposta a um tratamento de uma leucemia; método para prever um efeito clìnico de uma leucemia; método para selecionar um tratamento para um paciente com leucemia; método para o diagnóstico ou monitoramento de ocorrência, desenvolvimento, progressão ou tratamento de uma leucemia; arranjo para uso num método para prever um efeito clìnico para um paciente aml; arranjo para uso num método de diagnóstico de aml; meio legìvel por computador; kit para o prognóstico de aml |
| WO2006110593A2 (en) | 2005-04-07 | 2006-10-19 | Macrogenics, Inc. | Biological targets for the diagnosis, treatment and prevention of cancer |
| US20060252073A1 (en) * | 2005-04-18 | 2006-11-09 | Regents Of The University Of Michigan | Compositions and methods for the treatment of cancer |
| AU2006264567A1 (en) * | 2005-05-05 | 2007-01-11 | Valorisation Hsj, Societe En Commandite | Cytokine receptor modulators and uses thereof |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US20090215992A1 (en) * | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
| US7560530B1 (en) * | 2006-07-20 | 2009-07-14 | Schering Corporation | IL-33 receptor |
| CA2965198C (en) * | 2008-01-15 | 2021-02-16 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| AU2010208394A1 (en) * | 2009-01-27 | 2011-09-08 | Hologic, Inc. | Biomarkers for detection of neonatal sepsis in biological fluid |
| ES2571235T3 (es) * | 2009-04-10 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3 |
| GB2472856B (en) * | 2009-08-21 | 2012-07-11 | Cantargia Ab | IL1-RAP modulators and uses thereof |
| WO2011155607A1 (ja) * | 2010-06-11 | 2011-12-15 | 協和発酵キリン株式会社 | 抗ｔｉｍ－３抗体 |
| WO2012088302A2 (en) * | 2010-12-22 | 2012-06-28 | Abbott Laboratories | Half immunoglobulin binding proteins and uses thereof |
| WO2012088290A2 (en) * | 2010-12-22 | 2012-06-28 | Abbott Laboratories | Tri-variable domain binding proteins and uses thereof |
| RU2597831C2 (ru) | 2011-01-19 | 2016-09-20 | Кантаргия Аб | Анти-il1rap антитела и их применение при лечении людей |
| JP2014519480A (ja) | 2011-04-15 | 2014-08-14 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌で使用される抗ｉｌ−１ｒ１阻害物質 |
| CA2837651A1 (en) | 2011-06-21 | 2012-12-27 | Oncofactor Corporation | Compositions and methods for the therapy and diagnosis of cancer |
| WO2013023015A2 (en) | 2011-08-11 | 2013-02-14 | Albert Einstein College Of Medicine Of Yeshiva University | Targets for diagnosis, prognosis and therapy of acute myeloid leukemia and myelodysplastic syndromes |
-
2009
- 2009-03-26 JP JP2011502076A patent/JP2011515497A/ja not_active Withdrawn
- 2009-03-26 US US12/934,120 patent/US8709715B2/en active Active
- 2009-03-26 WO PCT/US2009/038459 patent/WO2009120903A2/en not_active Ceased
- 2009-03-26 EP EP09725022.9A patent/EP2271672B1/en not_active Not-in-force
- 2009-03-26 WO PCT/US2009/038455 patent/WO2009120899A2/en not_active Ceased
- 2009-03-26 US US12/810,006 patent/US20110044894A1/en not_active Abandoned
- 2009-03-26 WO PCT/US2009/038462 patent/WO2009120905A2/en not_active Ceased
- 2009-03-26 EP EP09726329.7A patent/EP2271673B1/en not_active Not-in-force
- 2009-03-26 CN CN2009801190867A patent/CN102046660A/zh active Pending
-
2013
- 2013-02-11 US US13/764,492 patent/US8715619B2/en active Active
-
2014
- 2014-04-03 US US14/244,698 patent/US9371390B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011515497A5 (https=) | ||
| JP2025020283A (ja) | 血液悪性腫瘍を処置するための抗ｌａｇ－３抗体 | |
| Camelliti et al. | Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know | |
| Linley et al. | Lectin binding to surface Ig variable regions provides a universal persistent activating signal for follicular lymphoma cells | |
| KR102757177B1 (ko) | 혈액성 악성종양에 대한 cd47 표적 요법을 위한 투약 파라미터 | |
| JP7511806B2 (ja) | 患者における抗ｃｄ１９治療の治療的有用性を予測するための方法 | |
| KR20140031905A (ko) | 다발성 골수종 환자에 대한 bcma-기본 계층화 및 치료법 | |
| RU2014118773A (ru) | Антитела к родственной раково-эмбриональному антигену молекуле клеточной адгезии (сеасам) | |
| Ribas et al. | Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion | |
| JP2013500976A5 (https=) | ||
| Chavez et al. | Targeting the inducible T-cell costimulator (ICOS) in patients with relapsed/refractory T-follicular helper phenotype peripheral T-cell and angioimmunoblastic T-cell lymphoma | |
| Sotomayor et al. | Clinical roundtable monograph: CD30 in lymphoma: its role in biology, diagnostic testing, and targeted therapy | |
| KR20230038318A (ko) | 불응성 호지킨 림프종에서의 니볼루맙을 사용한 pd-1 차단 | |
| WO2012142411A1 (en) | Systems and methods for detecting hent1 expression in hematological disorders | |
| Shree et al. | A phase I clinical trial adding OX40 agonism to in situ therapeutic cancer vaccination in patients with low-grade b-cell lymphoma highlights challenges in translation from mouse to human studies | |
| Hock et al. | Functional effects of immune complexes formed between pembrolizumab and patient-generated anti-drug antibodies | |
| JP2018528213A5 (https=) | ||
| Subramanyam | Case study: immunogenicity of natalizumab | |
| Schwickart et al. | Evaluation of assay interference and interpretation of CXCR4 receptor occupancy results in a preclinical study with MEDI 3185, a fully human antibody to CXCR 4 | |
| WO2018200473A1 (en) | Detection and targeting of tumor-promoting neutrophils cross-reference to related applications | |
| JP6195716B2 (ja) | 抗癌剤耐性診断マーカー | |
| WO2022184615A1 (en) | Novel biomarkers and uses thereof | |
| JP2017502285A (ja) | 抗体の分析 | |
| BR112018074603B1 (pt) | Método para identificar um sujeito tendo leucemia linfocítica crónica, e anticorpo anti-cd19 | |
| HK40023801B (zh) | 针对血液恶性肿瘤的cd47靶向疗法的给药参数 |